Quality Diabetes Care


Call us on: 01483 755 133
Follow us on:

Follow us on:


Study Shows Patients Prefer Revolutionary Foot Foam Moisturisers to Creams & Lotions

Back in 2016, we partnered with Neubourg Skin Care to bring a new urea based foot foam cream to the UK market – GlucoRx Allpresan®- . There are now thousands of patients with diabetes regularly using GlucoRx Allpresan as part of their daily regimen to reduce the risks of them developing a diabetic foot ulcers, So what exactly is it that makes our foam so great?

Why Foam?

While urea-based products are highly effective at preventing calluses (dry skin) on the feet of patients with diabetes, one of the main problems with some of these creams and lotions is that they can make the foot feel oily / greasy which in turn increases the risks of slips

GlucoRx Allpresan® is a unique foam-based product which, delivers intense moisture deep into the skin without leaving wetness on the surface.

Its patented technology means that unlike other creams / ointments GlucoRx Allpresan can be safely applied between the toes if required.

An Urgent Need for Improved Foot Care

Here at GlucoRx, we realised that there was an urgent need for a highly effective, low-risk solution to dry feet in patients with Diabetes, which is why we chose to expand our product range to include GlucoRx Allpresan®.

The importance of foot care is often overlooked, yet it’s one of the simplest ways to improve the quality of life of the diabetes population.

Considering that skin ulcers are a leading cause of lower limb amputations in people with diabetes, and that there are around 7000 of these amputations in England every year according to Diabetes UK. With only half of amputees with diabetes surviving more than two years after the procedure — a mortality rate much worse than many forms of cancer — something has to be done.

And that’s where GlucoRx Allpresan® comes in. By making safe and effective dry skin solutions available to people with Type 1 and Type 2 diabetes, we’re helping GlucoRx users to take control of their own health to prevent long term complications with their feet.

About GlucoRx Allpresan®

Right now, GlucoRx Allpresan® is the only approved, clinically-formulated diabetic foot foam cream that’s scientifically shown to deliver and lock in enough moisture to minimise the risk of calluses and prevent dry skin, which are two of the biggest risk factors for ulcers. It’s got many great benefits, including:

  • Non-greasy feel
  • Delivers moisture directly to the skin without leaving dampness
  • Quick to apply, and dressings and footwear can be worn immediately after application
  • Can be used on every part of the foot, even in places where creams and lotions can’t
  • Lasts twice as long as conventional creams, helping to save you money
  • Available of FP10 prescription and is stocked by a variety of community and online pharmacists.

Find Out More

To improve your own diabetic foot care and learn exactly why so many GlucoRx users prefer foam-based foot moisturisers over creams and lotions, give GlucoRx Allpresan® a try. Pop in and speak to your local pharmacist, or chat with your GP or diabetic nurse to see if a GlucoRx Allpresan® could be right for you.

Read More

GlucoRx 6th at Super Growth Awards 2019!

Chris Chapman is delighted at GlucoRx’s achievement at the Surrey Super Growth Awards this year, ranking 6th out of 50,000 companies.  

Lloyds Bank, asb law, and RSM compiled a shortlist of finalists based on profitable turnover growth over a four-year accounting period, using information filed at Companies House.

It was the first time GlucoRx attended the Super Growth Awards, being one of the top 50 companies invited to the Awards’ Breakfast.  

The Surrey Super Growth Awards commented on GlucoRx in their top 50 published list. “It was great to be recognised for all the good work our Company has been doing, not only locally but across the whole of the UK”, said Chris Chapman.

GlucoRx would like to congratulate the 2019 winners ‘Stenball Group Limited’ with their winning growth of 267%, and look forward to qualifying for next year’s 2020 awards.

Read More